The primary study objective is to evaluate the clinical efficacy of intracranial administration of SB623 cells, using the Fugi-Meyer Motor Score (FMMS) as the primary endpoint measure. Stroke is a major cause of prolonged neurological disability in adults with an economic burden of over $62 billion in the US. Of those who experience ischemic stroke, approximately one quarter will not survive. Of the survivors, more than a third will remain functionally dependent due to their physical and
Who may be Eligible
Patients 6 months post stroke with hemiparesis; Severe motor disability; Surgical intervention for ischemic stroke, chronic and acute; DNA modified cells to treat hemiplegia from ischemic stroke.